Retrospective review shows no major mortality difference in MRSA bacteremia treated with vancomycin or alternatives, suggesting ICU risk with vancomycin.
Key Points
This analysis aims to compare the outcomes of MRSA bacteremia patients treated with vancomycin versus non-vancomycin agents.
Retrospective cohort study of MRSA bacteremia cases from medical records
Comparison of inpatient mortality and other clinical outcomes
Utilization of multivariate logistic regression and linear regression for statistical analysis
88 hospitalizations analyzed with no significant mortality difference (VP: 12% vs NVP: 5.3%)
Charlson Comorbidity Index and Pitt Bacteremia Score predicted inpatient mortality
Vancomycin treatment associated with increased ICU admissions, but no other significant differences in clinical metrics.